Clinical Trial Update: A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease [Phase 1]

View source ↗

Summary

This phase 1 trial update evaluates safety, pharmacokinetics, pharmacodynamics, and immunogenicity of the anti-amyloid beta antibody MABT5102A in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MABT5102A (MABT5102A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED